NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Memorial Sloan Kettering Cancer Center
Fuzhou General Hospital
Brigham and Women's Hospital
Eli Lilly and Company
Novartis
AstraZeneca
OHSU Knight Cancer Institute